Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Compass Pathways Plc ADR (CMPS)

Compass Pathways Plc ADR (CMPS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
The Next Great Biotech Boom Has Arrived

EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END

JNJ : 148.53 (-0.69%)
CMPS : 8.10 (-1.82%)
MNMD : 8.46 (-4.62%)
ATAI : 1.8700 (-5.08%)
ABBV : 167.80 (-1.03%)
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market

All three have exciting programs on the way.

VRTX : 400.76 (-1.02%)
CMPS : 8.10 (-1.82%)
CPRX : 15.12 (+2.65%)
Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript

CMPS earnings call for the period ending December 31, 2023.

CMPS : 8.10 (-1.82%)
Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.

The lofty target is closer to being within reach than it may seem at first.

CMPS : 8.10 (-1.82%)
This May be One of the Biggest Catalysts for Psychedelic Stocks in 2024

About 43.8 million adults in the U.S. experience a mental health issue in a given year, according to the National Institute of Mental Health (NAMI). Nearly 16 million of those adults live with major depression....

CMPS : 8.10 (-1.82%)
SEEL : 0.3010 (-7.98%)
ATAI : 1.8700 (-5.08%)
MNMD : 8.46 (-4.62%)
NUMI.TO : 0.0800 (-5.88%)
NUMIF : 0.0595 (-0.83%)
Breaking: The US FDA Just Granted Priority Review of an MDMA Treatment for PTSD

At the moment, about 14 million people live with PTSD just in the U.S. Unfortunately, despite extensive clinical research, PTSD is still a significant unmet medical need. However, that may soon change...

CMPS : 8.10 (-1.82%)
SEEL : 0.3010 (-7.98%)
ATAI : 1.8700 (-5.08%)
MNMD : 8.46 (-4.62%)
NUMI.TO : 0.0800 (-5.88%)
NUMIF : 0.0595 (-0.83%)
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

CYBN.NE : 0.4800 (-1.03%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 0.3550 (unch)
ATAI : 1.8700 (-5.08%)
MNMD : 8.46 (-4.62%)
SEEL : 0.3010 (-7.98%)
CMPS : 8.10 (-1.82%)
3 Big New Catalysts for Psychedelics Stocks in 2024

This could be the year that psychedelics stocks start to fly.

CMPS : 8.10 (-1.82%)
ATAI : 1.8700 (-5.08%)
Compass Pathways Plc (CMPS) Q3 2023 Earnings Call Transcript

CMPS earnings call for the period ending September 30, 2023.

CMPS : 8.10 (-1.82%)
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis

EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END

ABBV : 167.80 (-1.03%)
ATAI : 1.8700 (-5.08%)
CMPS : 8.10 (-1.82%)
MNMD : 8.46 (-4.62%)
JNJ : 148.53 (-0.69%)

Barchart Exclusives

3 Dividend Aristocrats to Buy on Every Dip
As markets get wobbly, here are three Dividend Aristocrats to add a little stability to any portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar